# Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

> **NCT03106779** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 233 (actual)

## Conditions studied

- Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** Asciminib
- **DRUG:** Bosutinib

## Key facts

- **NCT ID:** NCT03106779
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-26
- **Primary completion:** 2020-05-25
- **Final completion:** 2024-12-04
- **Target enrollment:** 233 (ACTUAL)
- **Last updated:** 2025-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03106779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03106779, "Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03106779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*